Novolog (TASE:NVLG) Stock Revenue Growth Meets A Sharp Profit Squeeze

Novolog (Pharm-Up 1966) comes into this earnings season with the stock at ₪0.74 and a mixed recent run, with a decline over the past week but a gain over the past month. The headline this quarter is not growth; it is the squeeze on profitability. Q2 2026 revenue of ₪451.9m was paired with only ₪0.6m in net income and a trailing twelve month loss, which keeps the pressure on a dividend that is not covered by earnings.

Is Novolog (Pharm-Up 1966) trading at a genuine discount on its low 0.2x P/S, or does the loss making record and DCF gap point to a value trap instead? See how the current market price compares with our independent valuation analysis for Novolog (Pharm-Up 1966)

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: ₪451.9m vs. ₪441.7m (up roughly 2%)
• Net Income, Q2 2026 vs. Q2 2025: ₪0.6m vs. ₪4.8m (decline of about 88%)
• Basic EPS, Q2 2026 vs. Q2 2025: ₪0.0011 vs. ₪0.0094 (decline of about 88%)
• Trailing 12 Month Net Income, Q2 2026 vs. Q2 2025: loss of ₪0.7m vs. profit of ₪20.1m (swing from profit to loss)

Prefer clean, visual charts instead of another wall of earnings tables? See how Novolog (Pharm-Up 1966) compares on valuation in a single, unified view through the full company report for Novolog (Pharm-Up 1966).

Where The Novolog Bull Story Still Holds

For a bullish view on Novolog, the main support is that revenue is at least moving in the right direction. Q2 2026 sales of ₪451.9m are modestly higher than Q2 2025, which suggests the diversified healthcare platform is still attracting demand. For investors focused on the logistics and services backbone, that top line resilience can matter more than one quarter of thin profit, especially when the business spans essential pharma distribution, labs and digital tools that are embedded in everyday healthcare activity.

How Recent Results Feed The Bear View

The bearish narrative finds more direct backing in these numbers. Net income in Q2 2026 fell sharply to ₪0.6m from ₪4.8m and the trailing twelve month line moved from a profit of ₪20.1m to a loss of ₪0.7m. That raises questions about margin pressure across Novolog’s logistics, lab and digital operations. With earnings not covering the dividend and the share price down over the past week and past quarter, the immediate concern is less about growth stories and more about restoring consistent profitability.

Review whether Novolog’s thin profits and uncovered dividend are isolated issues or early signals of deeper structural strain. Expose the full risk analysis for Novolog (Pharm-Up 1966) which shows 2 important warning signs.

Stay Ahead With Simply Wall St

If Novolog (Pharm-Up 1966) is on your radar after this earnings update, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the profit story evolves. After you take a position, keep your focus on what matters by using the Portfolio Command Center to cut through noise and surface only the most important developments for your holdings. For a broader view on sentiment and potential catalysts, tap into the collective insight of other investors through the Community. This way you can spot both hidden risks and emerging drivers early and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Novolog Today

Fresh stock ideas can move from quiet to flying quickly. Use curated screeners to spot potential breakouts before the crowd catches up and the edge drops.

• Scan for potential quality at a discount by reviewing a hand picked 270 high quality undervalued stocks that still sit under the radar for now.
• Target resilient compounding potential by checking a curated 292 resilient stocks with low risk scores that aim to keep downside in check while momentum builds elsewhere.
• Assess the build out of future AI infrastructure by reviewing 55 AI infrastructure stocks that could benefit as demand for compute capacity and data centers evolves.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com